Migraine Disorders
Conditions
Keywords
migraine, triptan
Brief summary
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Detailed description
There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication. There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment. The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan. Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.
Interventions
DRUGSumatriptan
Register the response to treatment and headache characteristics.
Sponsors
Instituto de Salud Carlos III
Hospital Universitari Vall d'Hebron Research Institute
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Migraine with or without aura diagnosis according to ICHD-3 criteria * \<8 migraine days per month * Be able to read, write and understand instructions. * Have internet access and mail address * Signing of the informed consent
Exclusion criteria
* Active preventive treatment for migraine * Active medication with an effect over the central nervous system * Serious physical or psychiatric condition * Cardiovascular or hepatic disease * Pregnant or breastfeeding women * Any triptan contraindication * Severe migraine attacks without previous response to triptans or NSAIDs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to sumatriptan | 24 hours | Relief of pain from moderate-severe to mild or absent at 2 hours and 24 hours in 3 out of 4 migraine attacks. The response will be evaluated via questionnaire. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Migraine characteristics | 24 hours | Patients will complete a questionnaire describing the characteristics of migraine attacks in the beginning of the attack, and at timepoints 2 and 24 hours after taking sumatriptan. |
Countries
Spain
Contacts
Primary ContactMarta Torres-Ferrús, PhD
Outcome results
None listed